Landos Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-21.94	-39.28	-38.42	-30.14	-13.47	-6.04
Depreciation & Amortization	0	0.58	0.2	0.14	0.1	0.08
Share-Based Compensation	0.97	1.97	4.12	0.87	0.05	0.05
Other Operating Activities	0.49	-9.04	7.05	6.17	3.44	-0.99
Operating Cash Flow	-20.48	-45.77	-27.06	-22.96	-9.87	-6.9
Capital Expenditures	0	0.23	-0.44	-0.18	-0.16	-0.04
Change in Investments	7.78	73.83	-58.27	14.31	-40.17	0
Investing Cash Flow	7.78	74.06	-58.71	14.13	-40.33	-0.04
Share Issuance / Repurchase	13.57	0	93.51	1.52	0	0
Debt Issued / Paid	0	0	0	0	7.98	0
Other Financing Activities	-	-	-1.91	-	51.67	5
Financing Cash Flow	13.57	0	91.61	1.52	59.65	5
Exchange Rate Effect	0.04	0.05	0.05	-0.08	0	0
Net Cash Flow	0.87	28.29	5.84	-7.31	9.45	-1.94
Free Cash Flow	-20.48	-45.54	-27.5	-23.14	-10.03	-6.94
Free Cash Flow Per Share	-3.26	-11.31	-7.32	-18.93	-8.80	-6.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).